AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 208 filers reported holding AMICUS THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $707,000 | -97.9% | 65,788 | -98.2% | 0.00% | -96.0% |
| Q1 2022 | $33,794,000 | -45.7% | 3,568,514 | -33.7% | 0.02% | -35.9% |
| Q4 2021 | $62,200,000 | +14.8% | 5,385,270 | -5.0% | 0.04% | +11.4% |
| Q3 2021 | $54,158,000 | -2.5% | 5,671,041 | -1.6% | 0.04% | -5.4% |
| Q2 2021 | $55,543,000 | -1.9% | 5,761,685 | +0.5% | 0.04% | -9.8% |
| Q1 2021 | $56,647,000 | -50.4% | 5,733,479 | +16.0% | 0.04% | -49.4% |
| Q4 2020 | $114,125,000 | +50.8% | 4,942,583 | -7.8% | 0.08% | +32.8% |
| Q3 2020 | $75,680,000 | -1.3% | 5,359,805 | +5.4% | 0.06% | -11.6% |
| Q2 2020 | $76,679,000 | +62.5% | 5,084,839 | -0.5% | 0.07% | +21.1% |
| Q1 2020 | $47,199,000 | -32.8% | 5,108,110 | -29.2% | 0.06% | -19.7% |
| Q4 2019 | $70,247,000 | +21.6% | 7,212,221 | +0.1% | 0.07% | +16.4% |
| Q3 2019 | $57,769,000 | -41.1% | 7,203,132 | -8.4% | 0.06% | -37.1% |
| Q2 2019 | $98,143,000 | -16.3% | 7,864,010 | -8.8% | 0.10% | -16.4% |
| Q1 2019 | $117,299,000 | +24.6% | 8,624,937 | -12.2% | 0.12% | +10.5% |
| Q4 2018 | $94,117,000 | -22.7% | 9,824,372 | -2.5% | 0.10% | -6.2% |
| Q3 2018 | $121,770,000 | -22.8% | 10,071,964 | -0.2% | 0.11% | -27.3% |
| Q2 2018 | $157,680,000 | +1.4% | 10,094,767 | -2.3% | 0.15% | -0.6% |
| Q1 2018 | $155,445,000 | +11.3% | 10,335,467 | +6.5% | 0.16% | +12.3% |
| Q4 2017 | $139,613,000 | -5.3% | 9,702,113 | -0.7% | 0.14% | -8.6% |
| Q3 2017 | $147,362,000 | +63.8% | 9,772,025 | +9.4% | 0.15% | +58.9% |
| Q2 2017 | $89,963,000 | +39.6% | 8,933,758 | -1.1% | 0.10% | +37.7% |
| Q1 2017 | $64,424,000 | +39.7% | 9,035,667 | -2.6% | 0.07% | +35.3% |
| Q4 2016 | $46,111,000 | -21.2% | 9,277,910 | +17.3% | 0.05% | -19.0% |
| Q3 2016 | $58,508,000 | +108.2% | 7,906,476 | +53.6% | 0.06% | +103.2% |
| Q2 2016 | $28,104,000 | -35.3% | 5,147,214 | +0.1% | 0.03% | -32.6% |
| Q1 2016 | $43,442,000 | +8.6% | 5,141,046 | +24.7% | 0.05% | +17.9% |
| Q4 2015 | $40,002,000 | -28.4% | 4,123,955 | +3.3% | 0.04% | -31.6% |
| Q3 2015 | $55,832,000 | +17.0% | 3,990,817 | +18.4% | 0.06% | +29.5% |
| Q2 2015 | $47,714,000 | – | 3,371,995 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |